<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02268045</url>
  </required_header>
  <id_info>
    <org_study_id>RTXM83-AC-01-11</org_study_id>
    <nct_id>NCT02268045</nct_id>
  </id_info>
  <brief_title>Study of RTXM83 Plus CHOP Chemotherapy Versus a Rituximab Plus CHOP Therapy in Patients With Non Hodgkin's Lymphoma</brief_title>
  <official_title>A Randomized, Double-blind, Phase III Study Comparing Biosimilar Rituximab (RTXM83) Plus CHOP Chemotherapy Versus a Reference Rituximab Plus CHOP (R-CHOP) in Patients With Diffuse Large B-cell Lymphoma (DLBCL) Given as First Line</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>mAbxience S.A</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pisa Farmacética</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Laboratorios de Productos Éticos C.E.I.S.A.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Laboratorio Elea S.A.C.I.F. y A.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tecnoquímicas S.A.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Innogene Kalbiotech Pte. Ltd</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Libbs Farmacêutica LTDA</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Key Oncologics (Pty) Ltd</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Nanolek LLC</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Actoverco</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>mAbxience S.A</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study of RTXM83 plus CHOP chemotherapy versus a rituximab plus CHOP therapy in patients with
      Non Hodgkin's lymphoma The primary endpoint of the investigation is to determine if the
      response rate obtained with RXM83 combined with CHOP is non inferior to the response rate
      obtained with reference rituximab combined with CHOP The present study is a non inferiority
      trial and the study hypothesis is the following: H0: pc ≥ pe + δ vs. H1: pc &lt; pe + δ where,
      pe: proportion of successes in the experimental group (RTXM83+CHOP) pc: proportion of
      successes in the control group (Reference Rituximab+CHOP) Type I error: the difference pc-pe
      is less than δ when in fact the difference is greater than or equal to δ ie, the
      investigators choose the experimental treatment when the control treatment is actually
      substantially better.

      Type II error: the difference -pe is greater than or equal to δ when it is actually lest than
      δ ie, the investigators choose the control treatment when the experimental treatment is
      essentially just as good.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Actual">July 2017</completion_date>
  <primary_completion_date type="Actual">May 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response Rate</measure>
    <time_frame>Tumour response will be assessed after Cycle 6. Up to 13.5 months</time_frame>
    <description>Tumour responses will be assessed after 6 cycles of chemotherapy or at the end of treatment and classified as Complete Response (CR), Partial Response (PR), Stable Disease (SD) or Progressive Disease (PD) according to the International Working Group criteria.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate Event Free Survival (EFS) in both treatment arms</measure>
    <time_frame>The outcome measures are assessed in both treatment arms after 9 months of follow-up since last dose of chemotherapy. Up to 13.5 months</time_frame>
    <description>Time to progressive disease under therapy, the events for which being: progressive disease, no achievement of CR, PR associated with treatment in excess of that per protocol, SD, relapse after achievement of CR, death from any cause, whichever comes first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate Safety in both arms</measure>
    <time_frame>The outcome measures are assessed during the study up to 30 days after the end of study treatment. Up to 13.5 months</time_frame>
    <description>AEs will be collected during the study and up to 30 days after the end of study treatment (graded according to the NCICTC criteria [v 4.0]).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To demonstrate comparable pharmacokinetics of RTXM83 and Rituximab</measure>
    <time_frame>Cycle 1, 2, 3, 4, 5, 6, FU#1, FU#2, FU#3. Up to 13.5 months</time_frame>
    <description>Comparison of the variability of PK parameters of RTXM83 and MabThera® in a population PK analysis, and the 90% confidence intervals of the ratios of the means of bioequivalence (BE) parameters (AUC, Cmax) calculated from the population PK parameters evaluated for the two products.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To demonstrate comparable pharmacodynamics</measure>
    <time_frame>Cycle 1, 2, 4, 6, FU#1, FU#2, FU#3. Up to 13.5 months</time_frame>
    <description>Comparison of pharmacodynamic markers (decreased CD20+ and CD19+ cells) from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To compare immunogenicity between both arms</measure>
    <time_frame>Cycle 1, 5, 6, FU#1, FU#3. Up to 13.5 months</time_frame>
    <description>Comparison of immunogenicity (development of human antichimaeric antibodies (HACA) and human anti-murine antibodies (HAMA), and anti-Host-Cell Proteins (HCP) antibody between the two treatment arms.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">256</enrollment>
  <condition>Diffuse Large B-cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>RTXM83</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Active Ingredient: Rituximab (Biosimilar)
Rituximab biosimilar (RTXM83) will be administered in combination with CHOP chemotherapy regimen (Cyclophosphamide 750 mg/m2, Doxorubicin 50 mg/m2 and Vincristine 1.4 mg/m2 up to a maximum of 2 mg on Day 1 plus Prednisone 40 mg/m2 or 100 mg per day from Day 1 to 5) at a dose of 375 mg/m2 on Day 1 of each 3 week cycle, for 6 cycles, although the administration of 2 additional cycles may be allowed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MabThera</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Active Ingredient: Rituximab
MabThera will be administered in combination with CHOP chemotherapy regimen (Cyclophosphamide 750 mg/m2, Doxorubicin 50 mg/m2 and Vincristine 1.4 mg/m2 up to a maximum of 2 mg on Day 1 plus Prednisone 40 mg/m2 or 100 mg per day from Day 1 to 5) at a dose of 375 mg/m2 on Day 1 of each 3 week cycle, for 6 cycles, although the administration of 2 additional cycles may be allowed.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>RTXM83</intervention_name>
    <description>Rituximab biosimilar (RTXM83) will be administered in combination with CHOP chemotherapy regimen (Cyclophosphamide 750 mg/m2, Doxorubicin 50 mg/m2 and Vincristine 1.4 mg/m2 up to a maximum of 2 mg on Day 1 plus Prednisone 40 mg/m2 or 100 mg per day from Day 1 to 5) at a dose of 375 mg/m2 on Day 1 of each 3 week cycle, for 6 cycles, although the administration of 2 additional cycles may be allowed.</description>
    <arm_group_label>RTXM83</arm_group_label>
    <arm_group_label>MabThera</arm_group_label>
    <other_name>Rituximab Biosimilar</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients with measurable disease defined as existence of a unidimensional or
             bidimensional lesion greater than 2 cm in its longest diameter or malignant
             lymphocytosis greater than 5x109/L. Any other procedure for measurable disease in
             particular cases, may be allowed upon Sponsor approval

          2. Newly diagnosed patients with a confirmed pathologic diagnosis of large B
             cell-non-Hodgkin's lymphoma (DLBCL) with untreated CD20+. Defined by the local
             Haematopathologist at the local laboratory according to WHO criteria

          3. Stage II-III or IV or stage I with bulk defined by the referring physician on the
             basis of the Cotswolds modification of the Ann Arbor classification 2

          4. Age-adjusted International Prognostic Index (IPI) score 0 or 1

          5. Age ≥18 to ≤65 years of age

          6. Performance status (Eastern Cooperative Oncology Group [ECOG]) of ≤2

          7. Written informed consent obtained before starting any study-specific procedure

          8. Females of child-bearing potential must test negative on standard serum pregnancy test
             and must be willing to practice appropriate contraceptive methods for the duration of
             the study (e.g. oral contraceptive, double barrier method, intra-uterine device,
             intra-muscular contraceptive)

          9. All male patients must take adequate contraceptive precautions during the course of
             the study

        Exclusion Criteria:

          1. Life expectancy of less than three months

          2. Any other lymphoma other than CD20+ DLBCL

          3. Indolent lymphoma, Primary central nervous system (CNS) Lymphoma or gastro-intestinal
             Mucosa Associated Lymphoid Tissue (MALT) Lymphoma

          4. Known hypersensitivity to active ingredients, excipients and murine and foreign
             proteins

          5. Concurrent disease or general status that would exclude giving the treatment as
             outlined in the protocol

          6. Active uncontrolled infection requiring systemic treatment with antibiotics or
             antiviral agents at Screening or history of documented recurrent clinically
             significant infection (e.g. 2 or more viral, bacterial or fungal infections requiring
             inpatient treatment)

          7. Cardiac contra-indication to Doxorubicin therapy: non-compensated heart failure,
             dilated cardiomyopathy, coronary heart disease with ST segment depression on
             electrocardiogram (ECG), myocardial infarction in the last 6 months

          8. Neurologic contra-indication to Vincristine as it is indicated in the SmPC: (e.g.
             peripheral neuropathy)

          9. Chronic lung disease with hypoxemia measured by saturometer (gasometry is not
             mandatory)

         10. Severe uncontrolled hypertension, despite optimal medical treatment

         11. Severe uncontrolled diabetes mellitus, despite optimal medical treatment

         12. Renal insufficiency (Serum Creatinine&gt;2xUNL)

         13. Hepatic insufficiency (aspartate aminotransferase [AST]/alanine aminotransferase [ALT]
             &gt;3xUNL or &gt;5xUNL with involvement of the liver, total bilirubin &gt;34.2 µmol/L, or both)
             not related to lymphoma

         14. Clinical signs of cerebral dysfunction

         15. Severe psychiatric disease

         16. Known human immunodeficiency virus (HIV) infection or active chronic hepatitis B or C

         17. Abnormal bone marrow function (platelets &lt;100x109/L, neutrophils &lt;1.5x109/L and
             Haemoglobin &lt;9g/dL)

         18. Post-transplantation lymphoproliferative disease

         19. Pregnant or lactating women or women that intend to get pregnant during study or
             within 12 months following the last infusion

         20. Treatment with any investigational product in the 30 days period before inclusion in
             the study

         21. Prior radiotherapy to treat the DLBCL NHL

         22. Limitation of the patient's ability to comply with the treatment or follow-up protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Susana Millán, Phd</last_name>
    <role>Study Director</role>
    <affiliation>mAbxience S.A</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hosp. Interzonal &quot;R&quot; Carrillo</name>
      <address>
        <city>Ciudadela</city>
        <state>Bariloche</state>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica Radiologica del Sur</name>
      <address>
        <city>Cipolletti</city>
        <state>Río Negro</state>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica Viedma</name>
      <address>
        <city>Viedma</city>
        <state>Río Negro</state>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Britanico</name>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Gral. de Agudos Donación Francisco Santojanni</name>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Insituto Roffo</name>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Oncologico Riojano Integral (CORI)</name>
      <address>
        <city>Cordoba</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Nacional de Clinicas</name>
      <address>
        <city>Cordoba</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Privado de Cordoba</name>
      <address>
        <city>Cordoba</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanatorio Allende</name>
      <address>
        <city>Cordoba</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ctr. Oncologico de Rosario</name>
      <address>
        <city>Rosario</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inst. Cardiovascular Rosario</name>
      <address>
        <city>Rosario</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto de Hematología y Medicina Clínica Dr. Rubén Dávoli</name>
      <address>
        <city>Rosario</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanatorio Parque</name>
      <address>
        <city>Rosario</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundación ARS Médica</name>
      <address>
        <city>San Salvador de Jujuy</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital J. B. Iturraspe</name>
      <address>
        <city>Santa Fe</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Angel Padilla</name>
      <address>
        <city>Tucumán</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinicas Porto Alegre</name>
      <address>
        <city>Pôrto Alegre</city>
        <state>Rio Grande do Sul</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Caridade de Ijuí</name>
      <address>
        <city>Ijuí</city>
        <state>RS</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital da Cidade de Passo Fundo</name>
      <address>
        <city>Passo Fundo</city>
        <state>RS</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital São Lucas da PUCRS</name>
      <address>
        <city>Porto Alegre</city>
        <state>RS</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Santa Marcelina</name>
      <address>
        <city>Itaquera</city>
        <state>Sao Paulo</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Amaral Carvalho Jaú</name>
      <address>
        <city>Jaú</city>
        <state>SP</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto da Universidade de São Paulo-HCFMRP</name>
      <address>
        <city>Ribeirão Preto</city>
        <state>SP</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CEPHO - Centro de Estudos e Pesquisas de Hematologia e Oncologia / Faculdade de Medicina do ABC</name>
      <address>
        <city>Santo André</city>
        <state>SP</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundação Antônio Prudente - AC Camargo Câncer Center</name>
      <address>
        <city>Sao Paulo</city>
        <state>SP</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital das Clinicas-UFMG</name>
      <address>
        <city>Belo Horizonte</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UNICAMP-Univ Zeferino Vaz</name>
      <address>
        <city>Campinas</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Uniao Oeste Paranaense de Estudos e Comabte ao Cancer (UOPECCAN)</name>
      <address>
        <city>Cascavel</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Erasto Gaertner CEPEP</name>
      <address>
        <city>Curitiba</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital das Clínicas da Universidade Federal de Goiás</name>
      <address>
        <city>Goiânia</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Santa Casa de Porto Alegre</name>
      <address>
        <city>Porto Alegre</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitário Clemente Fraga Filho - UFRJ</name>
      <address>
        <city>Rio de Janeiro</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto COI de Educação e Pesquisa</name>
      <address>
        <city>Rio de Janeiro</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Est. de Hematologia Arthur de Siqueira Cavalcanti</name>
      <address>
        <city>Rio de Janeiro</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Monte Tabor - Hospital São Rafael</name>
      <address>
        <city>Salvador</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Pesquisa do Instituto Brasileiro de Controle do Câncer - IBCC</name>
      <address>
        <city>Sao Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinica Faculdade Medicina USP</name>
      <address>
        <city>Sao Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Base de São José</name>
      <address>
        <city>São José do Rio Prêto</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inst. Nacional de Cancerologia</name>
      <address>
        <city>Bogotá</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundación Valle de Lili</name>
      <address>
        <city>Cali</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Pablo Tobon Uribe</name>
      <address>
        <city>Medellin</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Srinivasam Cancer Care Hospital</name>
      <address>
        <city>Bangalore</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Institute</name>
      <address>
        <city>Chennai</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rajiv Gandhi Cancer Institute and Research Centre</name>
      <address>
        <city>Delhi</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bibi General Hospital&amp;Canc Ct</name>
      <address>
        <city>Hyderabad</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Birla Cancer Center - SMS Hospital</name>
      <address>
        <city>Jaipur</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Health Point Multi-specialty Hospital</name>
      <address>
        <city>Kolkata</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Hematology and Transfusion Medicine</name>
      <address>
        <city>Kolkata</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Netaji Subhash Chandra Bose Cancer Research Institute</name>
      <address>
        <city>Kolkata</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Acharya Tulsi Regional Cancer Treatment and Research Institute</name>
      <address>
        <city>Madurai</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Guru Hospital</name>
      <address>
        <city>Madurai</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meenakshi Mission Hospital</name>
      <address>
        <city>Madurai</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kailash Cancer Hospital and Research Centre</name>
      <address>
        <city>Vadodara</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Hasan Sadikin Hospital</name>
      <address>
        <city>Bandung</city>
        <country>Indonesia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dharmais N. C. Center</name>
      <address>
        <city>Jakarta</city>
        <country>Indonesia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Imam Khomeini Complex Hospital - Cancer Institute</name>
      <address>
        <city>Tehrān</city>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Sultanah Aminah</name>
      <address>
        <city>Johor Bahru</city>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Malaya Medical Centre - UMMC</name>
      <address>
        <city>Kuala Lumpur</city>
        <zip>59100</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Miriam Cancer Hospital</name>
      <address>
        <city>Pulau Pinang</city>
        <zip>11200</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Pulau Pinang</name>
      <address>
        <city>Pulau Pinang</city>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Insituto Nacional de Cancerología</name>
      <address>
        <city>Mexico City</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Privado de Hematologia e Investigaciona Clinica</name>
      <address>
        <city>Asunción</city>
        <country>Paraguay</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cebu Doctors University Hospital</name>
      <address>
        <city>Cebu</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Perpetual Succour Hospital</name>
      <address>
        <city>Cebu</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Davao Doctors Hospital</name>
      <address>
        <city>Davao</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Kidney and Transplant Institute</name>
      <address>
        <city>Quezon City</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Veterans Memorial Medical Center</name>
      <address>
        <city>Quezon City</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arkhangelsk Clinical Oncology Dispensary</name>
      <address>
        <city>Arkhangelsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kursk regional clinical oncology dispensary</name>
      <address>
        <city>Kursk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>N.N. Blokhin Russian Cancer Research Cente</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Medical Surgical Center n.a. N.I. Pirogov</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Murmansk regional oncology dispensary</name>
      <address>
        <city>Murmansk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Budgetary Healthcare Institution of Stavropol region &quot;Pyatigorsk oncology center&quot;</name>
      <address>
        <city>Pyatigorsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rostov Scientific Research Oncology Institute</name>
      <address>
        <city>Rostov-na-Donu</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Russian Research Center for Radiology and Surgical Technologies</name>
      <address>
        <city>Saint-Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint-Petersburg State Budgetary Institution &quot;City Clinical Oncology Dispensary&quot;</name>
      <address>
        <city>Saint-Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Scientific Research Institute of Oncology n.a. N.N. Petrov</name>
      <address>
        <city>Saint-Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oncology Center # 2</name>
      <address>
        <city>Sochi</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Komi Republican Oncology Dispensary</name>
      <address>
        <city>Syktyvkar</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Healthcare Institution of Tula region &quot;Tula regional clinical hospital&quot;</name>
      <address>
        <city>Tula</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Republican Clinical Oncology Dispensary</name>
      <address>
        <city>Ufa</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Volgograd Regional Clinical Oncology Center</name>
      <address>
        <city>Volgograd</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rainbow Oncology Centre</name>
      <address>
        <city>Amanzimtoti</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tygerberg Academic Hosp</name>
      <address>
        <city>Cape Town</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GVI Oncology</name>
      <address>
        <city>Port Elizabeth</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chris Hani Baragwanath Hospital</name>
      <address>
        <city>Soweto</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Brazil</country>
    <country>Colombia</country>
    <country>India</country>
    <country>Indonesia</country>
    <country>Iran, Islamic Republic of</country>
    <country>Malaysia</country>
    <country>Mexico</country>
    <country>Paraguay</country>
    <country>Philippines</country>
    <country>Russian Federation</country>
    <country>South Africa</country>
  </location_countries>
  <removed_countries>
    <country>Thailand</country>
  </removed_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 19, 2014</study_first_submitted>
  <study_first_submitted_qc>October 15, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 20, 2014</study_first_posted>
  <last_update_submitted>September 20, 2017</last_update_submitted>
  <last_update_submitted_qc>September 20, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Non-Hodgkin Lymphoma</keyword>
  <keyword>DLBCL</keyword>
  <keyword>Diffuse large b-cell lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Vincristine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

